Oncobiologics (OTLK) Competitors $1.39 +0.09 (+6.92%) Closing price 10/24/2025 04:00 PM EasternExtended Trading$1.38 0.00 (-0.36%) As of 10/24/2025 07:43 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock OTLK vs. CABA, CRBU, VOR, TRDA, EPRX, BDTX, PYXS, GNFT, ACRS, and TARAShould you be buying Oncobiologics stock or one of its competitors? The main competitors of Oncobiologics include Cabaletta Bio (CABA), Caribou Biosciences (CRBU), Vor Biopharma (VOR), Entrada Therapeutics (TRDA), Eupraxia Pharmaceuticals (EPRX), Black Diamond Therapeutics (BDTX), Pyxis Oncology (PYXS), GENFIT (GNFT), Aclaris Therapeutics (ACRS), and Protara Therapeutics (TARA). These companies are all part of the "pharmaceutical products" industry. Oncobiologics vs. Its Competitors Cabaletta Bio Caribou Biosciences Vor Biopharma Entrada Therapeutics Eupraxia Pharmaceuticals Black Diamond Therapeutics Pyxis Oncology GENFIT Aclaris Therapeutics Protara Therapeutics Oncobiologics (NASDAQ:OTLK) and Cabaletta Bio (NASDAQ:CABA) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their dividends, risk, profitability, institutional ownership, media sentiment, valuation, earnings and analyst recommendations. Which has better earnings & valuation, OTLK or CABA? Oncobiologics is trading at a lower price-to-earnings ratio than Cabaletta Bio, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioOncobiologicsN/AN/A-$75.37M-$0.57-2.44Cabaletta BioN/AN/A-$115.86M-$2.71-0.91 Does the media refer more to OTLK or CABA? In the previous week, Cabaletta Bio had 6 more articles in the media than Oncobiologics. MarketBeat recorded 7 mentions for Cabaletta Bio and 1 mentions for Oncobiologics. Oncobiologics' average media sentiment score of 1.62 beat Cabaletta Bio's score of 0.50 indicating that Oncobiologics is being referred to more favorably in the media. Company Overall Sentiment Oncobiologics Very Positive Cabaletta Bio Positive Which has more risk & volatility, OTLK or CABA? Oncobiologics has a beta of 0.56, meaning that its share price is 44% less volatile than the S&P 500. Comparatively, Cabaletta Bio has a beta of 3.01, meaning that its share price is 201% more volatile than the S&P 500. Is OTLK or CABA more profitable? Oncobiologics' return on equity of 0.00% beat Cabaletta Bio's return on equity.Company Net Margins Return on Equity Return on Assets OncobiologicsN/A N/A -332.30% Cabaletta Bio N/A -92.11%-74.08% Do insiders & institutionals believe in OTLK or CABA? 11.2% of Oncobiologics shares are owned by institutional investors. 4.8% of Oncobiologics shares are owned by company insiders. Comparatively, 11.3% of Cabaletta Bio shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term. Do analysts recommend OTLK or CABA? Oncobiologics presently has a consensus price target of $7.00, indicating a potential upside of 403.60%. Cabaletta Bio has a consensus price target of $13.44, indicating a potential upside of 444.31%. Given Cabaletta Bio's stronger consensus rating and higher possible upside, analysts plainly believe Cabaletta Bio is more favorable than Oncobiologics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Oncobiologics 1 Sell rating(s) 4 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.14Cabaletta Bio 1 Sell rating(s) 1 Hold rating(s) 8 Buy rating(s) 1 Strong Buy rating(s) 2.82 SummaryCabaletta Bio beats Oncobiologics on 9 of the 14 factors compared between the two stocks. Get Oncobiologics News Delivered to You Automatically Sign up to receive the latest news and ratings for OTLK and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding OTLK and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart OTLK vs. The Competition Export to ExcelMetricOncobiologicsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$61.74M$3.46B$6.21B$10.81BDividend YieldN/A2.28%5.72%4.80%P/E Ratio-2.4428.5131.6030.99Price / SalesN/A497.40595.06133.64Price / CashN/A46.9537.2561.86Price / Book-0.4510.4012.056.61Net Income-$75.37M-$52.83M$3.34B$277.10M7 Day Performance6.11%2.10%1.94%2.57%1 Month Performance43.28%10.17%6.88%3.20%1 Year Performance-74.45%16.57%56.06%33.22% Oncobiologics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)OTLKOncobiologics2.8171 of 5 stars$1.39+6.9%$7.00+403.6%-74.4%$61.74MN/A-2.4420Positive NewsCABACabaletta Bio2.7396 of 5 stars$2.49+7.3%$13.44+439.9%-36.8%$227.75MN/A-0.9250Analyst ForecastHigh Trading VolumeCRBUCaribou Biosciences2.6314 of 5 stars$2.38-4.4%$6.67+180.1%+40.7%$221.63M$9.99M-1.34100News CoveragePositive NewsAnalyst ForecastVORVor Biopharma2.5118 of 5 stars$32.29+3.4%$113.83+252.5%N/A$221.32MN/A-0.12140Analyst ForecastInsider TradeTRDAEntrada Therapeutics3.3953 of 5 stars$5.81-4.6%$25.67+341.8%-59.8%$221.01M$210.78M-3.26110News CoverageAnalyst ForecastEPRXEupraxia Pharmaceuticals2.8565 of 5 stars$6.05-0.3%$11.00+81.8%+112.0%$217.56MN/A-7.1229Analyst ForecastShort Interest ↑BDTXBlack Diamond Therapeutics3.8734 of 5 stars$3.80-7.1%$11.00+189.5%+31.9%$216.35M$70M16.5290Positive NewsAnalyst ForecastPYXSPyxis Oncology2.8863 of 5 stars$3.45-6.8%$7.75+124.6%-5.5%$213.97M$16.15M-2.1660Analyst ForecastHigh Trading VolumeGNFTGENFIT2.0781 of 5 stars$4.25flat$7.00+64.7%-22.1%$212.51M$41.52M0.00120Positive NewsGap DownACRSAclaris Therapeutics2.5193 of 5 stars$1.91+2.1%$8.71+356.2%+27.2%$206.91M$16.79M-1.39100Positive NewsTARAProtara Therapeutics1.8112 of 5 stars$5.34+2.3%$19.60+267.0%+125.7%$206.03MN/A-3.3030News CoverageAnalyst Forecast Related Companies and Tools Related Companies Cabaletta Bio Competitors Caribou Biosciences Competitors Vor Biopharma Competitors Entrada Therapeutics Competitors Eupraxia Pharmaceuticals Competitors Black Diamond Therapeutics Competitors Pyxis Oncology Competitors GENFIT Competitors Aclaris Therapeutics Competitors Protara Therapeutics Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:OTLK) was last updated on 10/26/2025 by MarketBeat.com Staff From Our PartnersU.S. Government Sparking Crypto RallyMissed Bitcoin when it was $100? You’re not alone. Crypto runs in cycles—and the next one is already underw...Crypto 101 Media | SponsoredA Worldwide Gold Lockdown Is Now UnderwayCentral banks around the world are hoarding gold at one of the fastest rates in history — and former Goldman S...Stansberry Research | SponsoredElon Musk is on the lineElon Musk says November 6 could "affect the future of the world" Get ready for the biggest pivot in corpora...Altimetry | SponsoredTrump’s new nightmare beginsPorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | SponsoredBuy the dip? Here’s my #1 gold stock“The most obvious opportunity in gold stocks I’ve seen in my career” While everyone is distracted by gold’s...Golden Portfolio | SponsoredThe strategy that wins no matter where the market goesJoel and Adam have built a crypto trading system with a 93% win rate — even through volatile, sideways markets...Crypto Swap Profits | SponsoredNvidia x 1,000,000Nvidia’s latest AI chip is a $25,000 powerhouse — with 80 billion transistors and the ability to perform 60 tr...Paradigm Press | SponsoredIf You Keep Cash In A U.S. Bank Account… Read This NOWThe Treasury Department just issued a stunning warning: U.S. banks could lose up to $6.6 trillion of custom...Banyan Hill Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Oncobiologics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Oncobiologics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
